https://www.selleckchem.com/pr....oducts/brefeldin-a.h
rth rates. The aim of this study was to understand how demographic and treatment-related factors impact responses to fostemsavir-based regimens. BRIGHTE is an ongoing phase 3 study evaluating twice-daily fostemsavir 600 mg and optimized background therapy (OBT) in heavily treatment-experienced individuals failing antiretroviral therapy with limited treatment options (Randomized Cohort 1-2 and Nonrandomized Cohort 0 fully active antiretroviral classes). Virologic response rates (HIV-1 RNA 40 copies/ml, Snapshot analysis) and CD4+
Like
Comment
Share
